In addition, Cyclin-dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion is one of the molecular alterations that support CNS WHO grade 3 designations for meningiomas [2]. This evidence concerns the gene CDKN2A and meningioma.